Francis Kalemeera

Dr. Francis Kalemeera

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2022 in Expert Opinion on Drug Safety
Verified
Journal Article
Open access
BGBrian Godman
Brian Godman
AEAbiodun Egwuenu
Abiodun Egwuenu
EWEvelyn Wesangula
Evelyn Wesangula
Natalie SchellackNatalie Schellack
Natalie Schellack
AKAubrey Chichonyi Kalungia
Aubrey Chichonyi Kalungia
ABAdrian J Brink
Adrian J Brink
Antimicrobial resistance (AMR) is a concern as this increases morbidity, mortality, and costs, with sub-Saharan Africa having the highest rates globally. Concerns with rising AMR have resulted in i...

2 January 2020 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
BGBrian Godman
Brian Godman
HMHolly McCabe
Holly McCabe
TLTrudy Leong
Trudy Leong
DMDebjani Mueller
Debjani Mueller
AMAntony P. Martin
Antony P. Martin
Johanna Catharina MeyerJohanna Catharina Meyer
Johanna Catharina Meyer
Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed.

14 October 2017 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
MNM. M. Nashilongo
M. M. Nashilongo
BSBonifasius Siyuka Singu
Bonifasius Siyuka Singu
FKFrancis Kalemeera
Francis Kalemeera
MMM. Mubita
M. Mubita
ENE. Naikaku
E. Naikaku
DKDan Kibuule
Dan Kibuule
Namibia has the highest burden and incidence of hypertension in sub-Sahara Africa. Though non-adherence to antihypertensive therapy is an important cardiovascular risk factor, little is known about potential ways to improve adherence in Namibia following universal access. The objective of this study is to validate the Hill-Bone compliance scale and determine the level and predictors of adherence to antihypertensive treatment in primary health care settings in sub-urban townships of Windhoek, Namibia.

13 December 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
Etando AyukafanghaEtando Ayukafangha
Etando Ayukafangha
AAAdefolarin A. Amu
Adefolarin A. Amu
MHMainul Haque
Mainul Haque
Natalie SchellackNatalie Schellack
Natalie Schellack
Amanj KurdiAmanj Kurdi
Amanj Kurdi
BGBrian Godman
Brian Godman
Background: Multiple measures introduced early to restrict COVID-19 have dramatically impacted the teaching of medical and pharmacy students, exacerbated by the lack of infrastructure and experience with e-learning at the start of the pandemic. In addition, the costs and reliability of the Internet across Africa pose challenges alongside undertaking clinical teaching and practical programmes. Consequently, there is a need to understand the many challenges and how these were addressed, given increasingly complex patients, to provide future direction. Method: An exploratory study was conducted among senior-level medical and pharmacy educators across Africa, addressing four key questions, including the challenges resulting from the pandemic and how these were dealt with. Results: Staff and student members faced multiple challenges initially, including adapting to online learning. In addition, concerns with the lack of equipment (especially among disadvantaged students), the costs of Internet bundles, and how to conduct practicals and clinical teaching. Multiple activities were undertaken to address these challenges. These included training sessions, developing innovative approaches to teaching, and seeking ways to reduce Internet costs. Robust approaches to practicals, clinical teaching, and assessments have been developed. Conclusions: Appreciable difficulties to teaching arising from the pandemic are being addressed across Africa. Research is ongoing to improve education and assessments.

14 March 2020 in Hospital Practice
Verified
Journal Article
Closed access
BGBrian Godman
Brian Godman
DBDebashis Basu
Debashis Basu
YPYogan Pillay
Yogan Pillay
PAPaulo H. R. F. Almeida
Paulo H. R. F. Almeida
JMJulius C. Mwita
Julius C. Mwita
Johanna Catharina MeyerJohanna Catharina Meyer
Johanna Catharina Meyer
Currently about 19 million people in Africa are known to be living with diabetes, mainly Type 2 diabetes (T2DM) (95%), estimated to grow to 47 million people by 2045. However, there are concerns wi...

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
BGBrian Godman
Brian Godman
MWMagdalene Wladysiuk
Magdalene Wladysiuk
SMStuart McTaggart
Stuart McTaggart
Amanj KurdiAmanj Kurdi
Amanj Kurdi
EAEleonora Allocati
Eleonora Allocati
BWBjorn Wettermark
Bjorn Wettermark
Background. Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long‐acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long‐acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior‐level personnel. Results. Typically increasing use of long‐acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long‐acting insulin analogues lose their patents to benefit all key stakeholder groups. Conclusions. There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed.